SAVARA INC (SVRA) Stock Overview
USA - NASDAQ:SVRA - US8051111016 - Common Stock
SVRA Key Statistics, Chart & Performance
The current stock price of SVRA is 3.52 USD. In the past month the price increased by 7.65%. In the past year, price decreased by -16.98%.
SVRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 389.72B | ||
| AMGN | AMGEN INC | 12.52 | 146.96B | ||
| GILD | GILEAD SCIENCES INC | 14.48 | 139.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.77 | 98.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.51B | ||
| ARGX | ARGENX SE - ADR | 76.77 | 43.55B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.7 | 38.76B | ||
| INSM | INSMED INC | N/A | 28.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
| NTRA | NATERA INC | N/A | 22.37B | ||
| BIIB | BIOGEN INC | 8.58 | 20.14B |
Related stock screener links
About SVRA
Company Profile
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 59 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Company Info
SAVARA INC
6836 Bee Cave Road, Building 3, Suite 201
Austin TEXAS 78746 US
CEO: Matthew Pauls
Employees: 59
Phone: 151285113796
SAVARA INC / SVRA FAQ
What is the stock price of SAVARA INC today?
The current stock price of SVRA is 3.52 USD. The price increased by 1.44% in the last trading session.
What is the ticker symbol for SAVARA INC stock?
The exchange symbol of SAVARA INC is SVRA and it is listed on the Nasdaq exchange.
On which exchange is SVRA stock listed?
SVRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SAVARA INC stock?
13 analysts have analysed SVRA and the average price target is 9.98 USD. This implies a price increase of 183.56% is expected in the next year compared to the current price of 3.52. Check the SAVARA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SAVARA INC worth?
SAVARA INC (SVRA) has a market capitalization of 608.40M USD. This makes SVRA a Small Cap stock.
How many employees does SAVARA INC have?
SAVARA INC (SVRA) currently has 59 employees.
What are the support and resistance levels for SAVARA INC (SVRA) stock?
SAVARA INC (SVRA) has a support level at 3.51 and a resistance level at 3.66. Check the full technical report for a detailed analysis of SVRA support and resistance levels.
Should I buy SAVARA INC (SVRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SVRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SVRA, evaluating the profitability, health, valuation and growth aspects
- SAVARA INC (SVRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SAVARA INC (SVRA) Sales and EPS estimates to see what analysts future expectations are.
- SAVARA INC (SVRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SAVARA INC (SVRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- SAVARA INC (SVRA) Stock Chart to make your own analysis
- SAVARA INC (SVRA) Latest news and press-releases to stay up to date.
Does SAVARA INC (SVRA) stock pay dividends?
SVRA does not pay a dividend.
When does SAVARA INC (SVRA) report earnings?
SAVARA INC (SVRA) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of SAVARA INC (SVRA)?
SAVARA INC (SVRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
What is the Short Interest ratio of SAVARA INC (SVRA) stock?
The outstanding short interest for SAVARA INC (SVRA) is 10.31% of its float. Check the ownership tab for more information on the SVRA short interest.
SVRA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SVRA. When comparing the yearly performance of all stocks, SVRA is one of the better performing stocks in the market, outperforming 81.34% of all stocks.
SVRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SVRA. SVRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SVRA Financial Highlights
Over the last trailing twelve months SVRA reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -19.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.37% | ||
| ROE | -91.57% | ||
| Debt/Equity | 0.25 |
SVRA Forecast & Estimates
13 analysts have analysed SVRA and the average price target is 9.98 USD. This implies a price increase of 183.56% is expected in the next year compared to the current price of 3.52.